Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival: Clinical article Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Brain Neoplasms
  • Melanoma
  • Radiosurgery

abstract

  • The survival of patients with melanoma brain metastases managed with ipilimumab and definitive radiosurgery can exceed the commonly anticipated 4-6 months. Using ipilimumab in a supportive treatment paradigm of radiosurgery for brain oligometastases was associated with an increased median survival from 4.9 to 21.3 months, with a 2-year survival rate of 19.7% versus 47.2%. This association between ipilimumab and prolonged survival remains significant even after adjustment for performance status without an increased need for salvage WBRT.

publication date

  • August 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3171/2012.5.JNS111929

PubMed ID

  • 22702482

Additional Document Info

start page

  • 227

end page

  • 33

volume

  • 117

number

  • 2